• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Chemours Guidance Cut And Inventory Probe Could Be A Game Changer For Chemours (CC)

    Simply Wall St·08/28/2026 21:22:23
    语音播报
    • Pomerantz LLP recently launched an investigation into The Chemours Company over potential securities law violations after the firm cut its full-year adjusted EBITDA guidance and revealed an oversupplied aftermarket channel driven by initial channel fill and excess inventory.
    • This combination of reduced guidance and questions about inventory management raises fresh concerns about Chemours’ internal controls, disclosure practices, and the resilience of its business model.
    • We will now examine how this investigation into Chemours’ reduced guidance and inventory issues could influence the company’s broader investment narrative.

    Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

    Chemours Investment Narrative Recap

    To own Chemours, you need to believe that demand for its refrigerants and advanced materials can offset ongoing PFAS costs and cyclical TiO₂ swings. The Pomerantz investigation, sparked by reduced EBITDA guidance and excess inventory, sharpens near term focus on Chemours’ credibility around forecasting and channel management, which now sits alongside PFAS liabilities as the key risk, while execution on Opteon growth remains the main near term catalyst.

    The recent US$22.5 million federal PFAS settlement with the EPA and WVDEP, plus up to US$90 million of mandated mitigation spend, is highly relevant here. It highlights how environmental and compliance obligations can directly affect Chemours’ cash flows at the same time that weaker guidance and aftermarket oversupply are raising questions about the resilience of its core earnings drivers.

    Yet, against this backdrop, investors should be aware of how unresolved PFAS liabilities and fresh questions around internal controls could...

    Read the full narrative on Chemours (it's free!)

    Chemours' narrative projects $6.6 billion revenue and $686.0 million earnings by 2029. This requires 4.7% yearly revenue growth and a $990.0 million earnings increase from -$304.0 million today.

    Uncover how Chemours' forecasts yield a $19.78 fair value, a 27% upside to its current price.

    Exploring Other Perspectives

    CC 1-Year Stock Price Chart
    CC 1-Year Stock Price Chart

    Some of the lowest analysts were already cautious, assuming Chemours might need US$6.6 billion of revenue and US$1.7 billion of earnings by 2029, so this kind of guidance cut and legal scrutiny could easily push their view even more pessimistic compared with more optimistic catalysts around PFAS resolution and Opteon growth.

    Explore 5 other fair value estimates on Chemours - why the stock might be worth over 2x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.